Last reviewed 2026-06-03 · How we verify

Adamexina (ADAMEXINE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Adamexina (generic name: ADAMEXINE) is a adamexine drug. It is currently in Phase 2 development.

Adamexina works by interacting with a specific molecular target to produce a therapeutic effect.

Adamexina is a small molecule. It is also known by the synonyms Adamexina and Adamexine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ADAMEXINE
Drug class	adamexine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Adamexina has a key that fits into one of those locks. When it does, it helps to unlock a specific process in the cell, which can help to treat a particular disease or condition. However, the exact lock and key mechanism of Adamexina is not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Adamexina CI brief — competitive landscape report
Adamexina updates RSS · CI watch RSS

Frequently asked questions about Adamexina

What is Adamexina?

Adamexina (ADAMEXINE) is a adamexine drug.

How does Adamexina work?

Adamexina works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Adamexina?

ADAMEXINE is the generic (nonproprietary) name of Adamexina.

What drug class is Adamexina in?

Adamexina belongs to the adamexine class. See all adamexine drugs at /class/adamexine.

What development phase is Adamexina in?

Adamexina is in Phase 2.

Drug class: All adamexine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing